Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref.no. WOCK/SEC/SE/2025-26/015 dated 1st June, 2026, please find enclosed the transcript of the Investor Meeting held on Thursday, 4th June, 2026, for your information and records.
Pursuant to Regulation 30 of SEBI (LODR), Regulations, 2015, please find enclosed herewith copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.
Pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015, we wish to inform you that the Company will hold an Investor Meet on Thursday, 4th June, 2026 at 4:00 pm IST.
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis"
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Secretarial Compliance Report for the year ended 31st March, 2026
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic , ZAYNICH (Zidebactum/ Cefepime), for treatment of complicated urinary tract infections including pyelonephritis with concurrent Gram- negative bacteremia"
ICRA Limited has upgraded the Credit Rating as given below: Long Term- Fund Based- Term Loan- Present Rating- A- (Stable); Previous Rating- BBB (Positive) Long Term/ Short Term- Fund Based- Present Rating- A- (Stable)/ A2+; Previous Rating- BBB (Positive)/ A3+ Long Term/ Short Term- Non Fund Based- Present rating- A(Stable)/ A2+; Previous Rating- BBB(Positive)/ A3+ Long Term/Short Term- Unallocated Limits- Present Rating -A (Stable)/ A2+; Previous rating- BBB (Positive)/ A3+
Monitoring Agency Report for quarter ended 31st March, 2026.
Change in Senior Management Personnel.
Submission pursuant to Regulation 30 (LODR)Regulations, 2015- Press Release
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 251.00 | 260.00 | 288.00 | 355.00 | 352.00 | 370.00 | 325.00 | 355.00 | 413.00 | 380.00 | 430.00 | 516.00 |
| YOY Revenue Growth % | 4.15% | 0.78% | 2.13% | 21.99% | 40.24% | 42.31% | 12.85% | 0% | 17.33% | 2.7% | 32.31% | 45.35% |
| Other Income | 6.00 | 6.00 | 5.00 | 24.00 | 27.00 | 11.00 | 6.00 | 14.00 | 25.00 | 30.00 | 27.00 | 55.00 |
| Total Income | 257.00 | 266.00 | 293.00 | 379.00 | 379.00 | 381.00 | 331.00 | 369.00 | 438.00 | 410.00 | 457.00 | 571.00 |
| Total Expenses + | 358.00 | 373.00 | 367.00 | 505.00 | 373.00 | 417.00 | 353.00 | 329.00 | 369.00 | 356.00 | 419.00 | 439.00 |
| Cost of Materials Consumed | 62.00 | 51.00 | 80.00 | 92.00 | 82.00 | 88.00 | 64.00 | 76.00 | 74.00 | 75.00 | 81.00 | 79.00 |
| Employee Benefit Expense | 63.00 | 63.00 | 59.00 | 62.00 | 62.00 | 65.00 | 71.00 | 64.00 | 68.00 | 88.00 | 78.00 | 79.00 |
| Other Expenses | 90.00 | 102.00 | 86.00 | 204.00 | 83.00 | 118.00 | 106.00 | 100.00 | 101.05 | 108.00 | 129.00 | 156.00 |
| Operating Profit | -107.00 | -113.00 | -79.00 | -150.00 | -21.00 | -47.00 | -28.00 | 26.00 | 44.00 | 24.00 | 11.00 | 77.00 |
| OPM % | -42.6% | -43.5% | -27.4% | -42.3% | -6% | -12.7% | -8.6% | 7.3% | 10.7% | 6.3% | 2.6% | 14.9% |
| Profit Before Tax + | -115.00 | -107.00 | -74.00 | -126.00 | 6.00 | -36.00 | -22.00 | 40.00 | 69.00 | 54.00 | 28.00 | 167.00 |
| Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax % | - | - | - | - | 0% | - | - | 0% | 0% | 0% | 0% | 0% |
| Profit After Tax | -115.00 | -107.00 | -74.00 | -126.00 | 6.00 | -36.00 | -22.00 | 40.00 | 69.00 | 54.00 | 28.00 | 167.00 |
| EPS (Basic) | -8.01 | -7.39 | -5.14 | -8.71 | 0.39 | -2.34 | -1.40 | 2.47 | 4.25 | 3.26 | 1.73 | 10.29 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,739.00 | 1,402.00 | 1,154.00 | 1,072.00 | 1,372.00 | 987.26 | 890.06 |
| YOY Revenue Growth % | 24.04% | 21.49% | 7.65% | -21.87% | 38.97% | 10.92% | - |
| Other Income | 137.00 | 55.00 | 41.00 | 67.00 | 38.00 | 40.73 | 43.02 |
| Total Income | 1,876.00 | 1,457.00 | 1,195.00 | 1,139.00 | 1,410.00 | 1,027.99 | 933.08 |
| Total Expenses + | 1,584.00 | 1,469.00 | 1,603.00 | 1,417.00 | 1,594.00 | 1,509.28 | 946.61 |
| Cost of Materials Consumed | 309.00 | 310.00 | 285.00 | 200.00 | 283.00 | 253.10 | 236.70 |
| Employee Benefit Expense | 313.00 | 262.00 | 247.00 | 240.00 | 261.00 | 293.36 | 325.46 |
| Other Expenses | 494.00 | 404.00 | 482.00 | 361.00 | 413.00 | 415.31 | 384.45 |
| Operating Profit | 155.00 | -67.00 | -449.00 | -345.00 | -222.00 | -522.02 | -56.55 |
| OPM % | 8.9% | -4.8% | -38.9% | -32.2% | -16.2% | -52.9% | -6.4% |
| Profit Before Exceptional | 292.00 | -12.00 | -408.00 | -278.00 | -184.00 | -481.29 | -483.68 |
| Exceptional Items | 25.00 | 0.00 | -14.00 | -235.00 | 0.00 | -142.48 | 0.00 |
| Profit Before Tax + | 317.00 | -12.00 | -422.00 | -513.00 | -184.00 | -623.77 | -483.68 |
| Tax Expense | 0.00 | 0.00 | 0.00 | -47.00 | -44.00 | -1,217.06 | -252.56 |
| Tax % | 0% | - | - | - | - | - | - |
| Profit After Tax | 317.00 | -12.00 | -422.00 | -466.00 | -140.00 | 593.29 | -231.12 |
| EPS (Basic) | 19.54 | -0.76 | -29.27 | -32.40 | -11.62 | 53.57 | -20.88 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 3,554.00 | 3,314.00 | 3,089.00 | 3,257.00 | 3,410.00 | 3,055.93 | 0.00 |
| Property, Plant & Equipment | 1,128.00 | 1,240.00 | 1,394.00 | 1,557.00 | 1,744.00 | 1,580.64 | 0.00 |
| Capital Work in Progress | 121.00 | 79.00 | 56.00 | 56.00 | 69.00 | 306.50 | 0.00 |
| Non-Current Investments | 297.45 | 297.00 | 297.00 | 297.00 | 297.00 | 297.27 | 0.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 224.00 | 36.00 | 55.00 | 68.00 | 84.00 | 103.02 | 0.00 |
| Current Assets + | 2,290.00 | 1,990.00 | 1,668.00 | 1,296.00 | 2,244.00 | 1,694.68 | 0.00 |
| Inventories | 533.00 | 426.00 | 321.00 | 363.00 | 387.00 | 347.47 | 0.00 |
| Trade Receivables | 846.00 | 612.00 | 566.00 | 551.00 | 1,292.00 | 954.77 | 0.00 |
| Cash and Cash Equivalents | 76.00 | 35.00 | 463.00 | 4.00 | 172.00 | 78.98 | 0.00 |
| Current Investments | 412.00 | 422.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 3,084.00 | 2,763.00 | 1,796.00 | 1,753.00 | 2,212.00 | 1,605.76 | 0.00 |
| Equity Share Capital | 81.00 | 81.00 | 77.00 | 72.00 | 72.00 | 55.39 | 0.00 |
| Other Equity | 3,003.00 | 2,682.00 | 1,719.00 | 1,681.00 | 2,140.00 | 1,550.37 | 0.00 |
| Non-Current Liabilities | 1,425.00 | 1,162.00 | 1,184.00 | 353.00 | 537.00 | 686.35 | 0.00 |
| Current Liabilities | 1,426.00 | 1,483.00 | 1,888.00 | 2,626.00 | 3,049.00 | 2,602.79 | 0.00 |
| Total Liabilities | 2,851.00 | 2,645.00 | 3,072.00 | 2,979.00 | 3,586.00 | 3,289.14 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 241.00 | -14.00 | 188.00 | 71.00 | -93.00 | -563.97 | 0.00 |
| Cash from Investing Activities | -193.00 | -900.00 | -75.00 | -3.00 | -244.00 | 1,014.34 | 0.00 |
| Cash from Financing Activities | -7.00 | 486.00 | 346.00 | -236.00 | 430.00 | -479.85 | 0.00 |
| Net Increase/Decrease in Cash | 41.00 | -428.00 | 459.00 | -168.00 | 93.00 | -29.48 | 0.00 |